Current studies are being conducted to ascertain the effectiveness and safety of oral nutrient solution supplementation in patients with esophageal cancer based on the current understanding of the role of the NLRP3 inflammasome in possible cancer promotion and therapy. Here, NLRP3 is linked to cancer.